

Joint Transnational Call for Proposals (2024) for

Identification or Validation of Targets for Personalised Medicine Approaches (PMTargets)

Pre-proposal application form

**Please note:**

* Proposals that do not meet the regional/national eligibility criteria and requirements will be declined without further review.
* All fields must be completed using “Calibri font, size 11” characters, single-spaced.  
  The page margins of this form shall be respected.
* Incomplete proposals (proposals missing any sections), proposals using a different format   
  or exceeding length limitations of any sections will be rejected without further review.
* Sections in “italics” are instructions and should be deleted.
* Joint proposals consist of two parts: 1) This pre-proposal form to present mainly   
  the description of the planned work, and 2) the electronic submission tool to   
  provide particularly individual partner information and financial plans.   
  **Both parts should be completed jointly by all applying consortium partners   
  and need to be started in due time.**
* In case of inconsistency between the information registered in the   
  submission tool and the information included in the PDF of this application   
  form, the **information registered in the submission tool shall prevail**.
* Refer to the “GUIDELINES FOR APPLICANTS” for information about the   
  proposal structure.
* Once completed, the pre-proposal must be converted in a single PDF   
  document before being uploaded to the submission website.

# General information

**Project title**

|  |
| --- |
|  |

**Acronym (max. 15 characters)**

|  |
| --- |
|  |

**Project duration (months)**

|  |
| --- |
|  |

**Total project costs (€)\***

|  |
| --- |
|  |

**Total requested budget (€)\***

|  |
| --- |
|  |

*\*Please make sure that the same figures are entered in the sections that need to be completed online (PT-Outline submission tool) and in the financial overview in section 7 of this form. Thousand separators and whole numbers should be used only (e.g. 200.000).*

# Keywords (from 5 up to 7)

*Please list 5 to 7 keywords describing your proposal.*

|  |
| --- |
|  |

# Scientific abstract (max. 2,000 characters, including spaces)

Please give a comprehensive and readable summary of the most important aims and methods of the project. Please note that if the project is selected for funding this abstract will be published in the newsletter and on the funding organisations’ websites.

|  |
| --- |
|  |

# Project consortium

***For the project coordinator (also indicated as “partner 0” in this form and as “coordinator” in the online submission forms) and each scientific partner*** *(others than the coordinator, including* ***also partners participating on own funding****), please fill in the following table. For patient organisations participating in the consortium as partners, lines can be added, if needed.*

*Reminder (eligibility criteria and consortium composition in the pre-proposal stage): 1) Maximum number of partners is 6, including the coordinator (no more than 2 partners from the same country), 2) Maximum number of partners can be 7 if the consortium includes a 3rd partner of the same country (condition: funding requested from at least 2 different funders of the respective country; applies to only one country per consortium). Patient organisations are not included in this calculation (for more details, please read the Call Text).*

***Attention: Detailed partner information have to be provided in the online submission forms (PT-Outline).***

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Name and Surname of the Principal investigator | Institution, Department, full Affiliations | City, Country | Type of entity:  University, Hospital, Research Institute, SME, Large Industry, Associations, other |
| Coordinator  (= Partner 0) |  |  |  |  |
| Partner 1 |  |  |  |  |
| Partner 2 |  |  |  |  |
| Partner 3 |  |  |  |  |
| Partner 4 |  |  |  |  |
| Partner 5 |  |  |  |  |
| *Partner 6\** |  |  |  |  |

\**Maximum number of partners can only be 7 (including the coordinator) if the consortium includes a 3rd partner of the same country (condition: funding requested from at least 2 different funders of the respective country; applies to only one country per consortium).*

# Project description (max. 5 pages)

*The following five subsections MUST be completed in these five pages:*

1. *Background, current state of the art. Highlight any prior work related to the proposal and preliminary results obtained by the consortium members;*
2. *Describe the work plan including the objectives, the rationale for Personalised Medicine, the companion biomarker approach and the methodology, highlighting the novelty, originality and feasibility of the project;*
3. *Explain how the proposal fits in the scope of the call and the Personalised Medicine dimension of the proposed work**, including the demonstration of the stratification potential of the* *suggested companion diagnostic biomarker (and the indication of existing data/previous work in this regard), and its added value to the scientific question addressed in the proposal;*
4. *Describe the knowledge gap, the unmet medical and patient/societal need, the technical or implementation challenge that is addressed by the proposed work and the potential health impact that the results of your proposed work will have;*
5. *Describe the added value of the transnational collaboration; sharing of resources (registries, diagnosis, biobanks, models, databases, diagnostic and informatics tools, etc.), platforms/infrastructures, harmonisation of data and sharing of specific know-how. If European infrastructures, e.g. BBMRI, ECRIN, EATRIS or ELIXIR (see also Guidelines of Applicants), are involved in the proposal, please outline. Please describe the added value of the multidisciplinary and inter-sectorial collaboration.*

# Diagram which compiles the work plan and timeline (max. 1 page)

*The diagram must demonstrate the work plan, timeline, sequencing of work packages, contribution of the partners to each work package and their interactions (i.e. time plan, Gantt and/or PERT or similar).*

# Responsible Research and Innovation (RRI) and other cross cutting issues (page limits as indicated below)

# General RRI aspects (max. 0,5 page)

***Responsible research and innovation (RRI)*** *is an approach that anticipates and assesses potential implications and societal expectations with regard to research and innovation, with the aim to foster the design of inclusive and sustainable research and innovation to ensure a true societal impact.*

*RRI implies that societal actors (researchers, healthcare systems, citizens, policy makers, industry, third sector organisations, etc.) work together during the whole research and innovation process in order to better align both the process and its outcomes with the values, needs and expectations of society.*

*As the involvement of societal groups is essential in RRI it is often connected to co-creation, co-design and co-production, methodologies in which R&I projects are structured to include stakeholders from the outset (e.g. end-users or interest groups), and is related to the general Open Science agenda. RRI can also involve interdisciplinarity, with the inclusion of expertise from the social sciences and humanities (SSH). Being inclusive also implies taking diversity seriously.*

*In EP PerMed, taking an RRI approach implies to take actions that may include to*

1. *Reflect on and anticipate the future known and unknown risks associated with a science or technology;*
2. *Include a broad range of stakeholders in the development of science and technologies, hence working multidisciplinary and intersectoral;*
3. *Reflect on the underlying assumptions and values driving a scientific research project; and*
4. *Respond to these processes by incorporating their outcomes into the design of research projects and funding programmes.*

*RRI is closely related to other cross-cutting issues, and actions can be taken that address both RRI and other important values, such as public/end-user engagement, open science or ethical assessments.*

***Explain how the project will demonstrate a commitment to investigating and addressing the social, ethical, political, environmental or cultural dimensions of the proposed research*** *(see also “Guidelines for Applicants” for support)****.***

# Stakeholder involvement (max. 0,5 page)

* *Describe the role and contribution of operational stakeholders (e.g. patient organisations, citizens or citizen representatives, local communities, schools, municipalities, local/regional/national NGOs, consumer organisations).*
* *Describe the level of involvement for each stage of the research.*
* *Explain reasoning behind involving/not involving certain stakeholders.*

# For projects with high potential of applicability at short/medium term (max. 0,5 page)

*Expected time for market and transfer to patients towards clinical and public health applications, pharmaceutical/health device applications, other industrial applications including market and end user’s scenario, quality of dissemination, exploitation and business plan.*

# Ethical considerations

*Please note: If research activities are undertaken in a non-European country, the applicants should verify that the research activities will follow the Ethical recommendations of the country where the research will be conducted as well as the EU Ethical recommendations. Full-proposals will be checked by an independent ethical board. You can already check* [*here*](https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/how-to-complete-your-ethics-self-assessment_en.pdf) *the Ethical Issues potentially raised by your proposal.*

*Please tick the respective box below: The proposal complies with ethical principles (including the highest standards of research integrity, as set out, for instance, in* [*the European Code of Conduct for Research Integrity*](https://allea.org/code-of-conduct/)*, and including, in particular, avoiding fabrication, falsification, plagiarism or other research misconduct).*

Yes  No

# In addition, two more pages can be added to the pre-proposal (page limits per optional section as indicated below)

* *List of references (max. 1 page)*
* *Page with diagrams, figures, etc. to support the work plan description (max. 1 page)*

# Financial plan of project budget (in €1): Please make sure that the same figures are entered in this section and the online form (PT-Outline submission tool)

*Please note that* ***not*** *all types of expenditure are fundable by all funding organisations (see the “Guidelines for Applicants” for details on the eligibility criteria and contact the relevant EP PerMed regional/national funding organisation). Thousand separators and whole numbers should be used only (e.g. 200.000).*

*Please adapt the table and add new columns in this section if patient organisations are included as partners.*

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Coordinator  (Partner 0) | | Partner 1 | | Partner 2 | | Partner 3 | | Partner 4 | | Partner 5 | | *Partner 6\** | |
| PI (group lead) |  | |  | |  | |  | |  | |  | |  | |
| Institution |  | |  | |  | |  | |  | |  | |  | |
| Country |  | |  | |  | |  | |  | |  | |  | |
| Funding organisation |  | |  | |  | |  | |  | |  | |  | |
| PROJECT COSTS (€)1 | Total *=*  *requested + in-kind* | Requested | Total *=*  *requested + in-kind* | Requested | Total *=*  *requested + in-kind* | Requested | Total *=*  *requested + in-kind* | Requested | Total *=*  *requested + in-kind* | Requested | Total *=*  *requested + in-kind* | Requested | Total *=*  *requested + in-kind* | Requested |
| Person Months |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Personnel € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Consumables € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Equipment € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Travel €2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Other direct costs €3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Overheads €4 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Subcontracting3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **TOTAL** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

1 Those countries whose currency is different than € shall include their national currency in brackets.

2 Travel expenses should include the participation of the coordinator and regional/national partner leads for at least two status seminars to present the project results.

3 e.g. subcontracting, provisions, licensing fees; may not be eligible costs in all countries (will be handled according legal framework and funding body regulations).

4 Overhead costs: funding according to regional/national legal framework and funding body regulations. Check the respective funding organisation Annex II “Guidelines for Applicants”.

\**Maximum number of partners can only be 7 (including the coordinator) if the consortium includes a 3rd partner of the same country (condition: funding requested from at least 2 different funders of the respective country; applies to only one country per consortium). Patient organisations are not included in this calculation (for more details, please read the Call Text).*

# Brief CVs of each Principal Investigator (max. 1 page per PI)

*Please provide a brief CV of the Project Coordinator (to be indicated as partner 0) and each Project Partner’s Principal Investigator (PI). Please complete the table below and replicate the table as required.* ***Please be reminded that partners participating on own funding and patient organisations/representatives participating as consortium partners should be also presented.***

*Each partner should be represented by a* ***single*** *Principal Investigator (co-PI’s are not accepted). Proposals with extra-CVs or with CVs not following the page limit per partner will be rejected* *(max. 1 page per PI, Calibri 11, single-spaced, the margins of the page are not allowed to be adapted).*

|  |  |
| --- | --- |
| Partner | Please indicate what applies: coordinator (partner 0), partner 1, partner 2, etc. |
| Personal information | First name, last name, academic title  Institution and department (complete name) |
| Expertise | Max: 200 words |
| Role within the consortium | Please indicate the work package the PI will be working in. |
| Publications | Please list your five most relevant publications of the last ten years |
| Additional information | Honours, awards, memberships or references; up to 5 relevant third-party funded projects conducted in the area in the past 5 years |

# SIGNATURE

***The following Data Privacy Notice applies:***

*By applying to the call, applicants consent to the use, processing and retention of their data, in line with the above notice and for the purposes of:*

* *processing and evaluating the application where processing shall be lawful - only if and to the extent that - processing is necessary for the performance of a task carried out in the public interest or in the exercise of official authority vested in the controller;*
* *administering any subsequent funding award;*
* *managing the funding organisation’s relationship with them;*
* *analysing and evaluating the call;*
* *reporting to the European Commission/ European Health and Digital Executive Agency (HaDEA) on the call;*
* *providing aggregate data to regional/national and European surveys and analyses;*
* *complying with audits that may be initiated by the funding organisations.*

*The members of the EP PerMed consortium may share an applicant’s data with third parties (some of which may be based outside the European Economic Area) in relation to the above activities including evaluators, auditors and the European Commission (or its agencies).*

*The members of the EP PerMed consortium may link the data that applicants provide in the application with regional/national, bibliographic or external research funding data which is available through public subscription-based databases (e.g. Scopus, Web of Science, etc.) or other regional, national or open datasets. The members of the EP PerMed consortium may also link the data that applicants provide in their application with future data that applicants provide as part of the ongoing management and reporting.*

*Data on funding organisations including contact details of Call Steering Committee[[1]](#footnote-2) (CSC) members are kept for the purpose of the call communication. The information will be published with prior consent of the respective management bodies.*

***In addition, the applicants declare their willingness to cooperate with the research consortium and they did not receive other public funds to accomplish any tasks described in the project proposal.***

*Digital signatures or scanned signatures are accepted. These signatures should be from the principal investigators (PI) listed in section 2. An official signature of the respective institutions is not necessary. Please add signature lines, if needed.*

**Signature Coordinator (Partner 0) (place, date, signature of PI):**

I declare my willingness to cooperate with the research consortium

I declare not receive other public funds to perform the described tasks in this application

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Signature Partner 1 (place, date, signature of PI):**

I declare my willingness to cooperate with the research consortium

I declare not receive other public funds to perform the described tasks in this application

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Signature Partner 2 (place, date, signature of PI):**

I declare my willingness to cooperate with the research consortium

I declare not receive other public funds to perform the described tasks in this application

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Signature Partner 3 (place, date, signature of PI):**

I declare my willingness to cooperate with the research consortium

I declare not receive other public funds to perform the described tasks in this application

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Signature Partner 4 (place, date, signature of PI):**

I declare my willingness to cooperate with the research consortium

I declare not receive other public funds to perform the described tasks in this application

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Signature Partner 5 (place, date, signature of PI):**

I declare my willingness to cooperate with the research consortium

I declare not receive other public funds to perform the described tasks in this application

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Signature Partner 6 (place, date, signature of PI):**

I declare my willingness to cooperate with the research consortium

I declare not receive other public funds to perform the described tasks in this application

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. Call Steering Committee: comprises a single representative from each country’s/region’s funding organisation [↑](#footnote-ref-2)